glofitamab-gxbm (Columvi)
Jump to navigation
Jump to search
Indications
* improves overall survival over rituximab[2]
Dosage
- pretreatment with 1 g intravenous obinutuzumab 7 days priot to the 1st dose of glofitamab
- cycle 1: day 8: 2.5 mg glofitamab IV; day 15: 10 mg IV
- cycle 2-12: 30 mg on day 1
- cycles lasted 21 days
* 1 mg/mL
Adverse effects
Mechanism of action
- CD20-CD3 bispecific monoclonal antiboduy
More general terms
References
- ↑ Dickinson MJ, Carlo-Stella C, Morschhauser F et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022 Dec 15;387(24):2220-2231. PMID: https://pubmed.ncbi.nlm.nih.gov/36507690 Clinical Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206913
- ↑ 2.0 2.1 Bassett M Glofitamab Regimen Improves Survival in DLBCL. Granted accelerated approval last year, bispecific antibody passes its confirmatory test. MedPage Today June 20, 2024 https://www.medpagetoday.com/meetingcoverage/eha/110740